EDITION OF SAT 21 NOV 2026
96 · GENERAL

Daraxonrasib combination shows early promise in metastatic pancreatic cancer trial

publishers 20articles 24first reported 19 Nov, 13:01 UTCdeveloping since 19 Nov · 4 editions

An experimental daily pill combined with chemotherapy produced encouraging responses in an early-stage trial involving 61 patients with newly diagnosed metastatic pancreatic cancer.

In the phase 1/2 study, daraxonrasib was given with gemcitabine and nab-paclitaxel. Tumours shrank or became undetectable in 60.7% of patients, while 90.2% achieved disease control, meaning their cancer shrank or stopped growing. Five patients, or 8.2%, had complete radiological responses, with no detectable tumours on CT scans.

After a median follow-up of 18 months, 76.6% of participants were alive one year after starting treatment. The median period before tumours returned or began growing again was 12.8 months. The findings were presented by Dr Wungki Park of Memorial Sloan Kettering Cancer Center at a cancer research symposium in Barcelona.

Daraxonrasib inhibits mutated KRAS proteins, which drive growth in most pancreatic cancers. Researchers cautioned that an undetectable tumour on imaging does not establish that a patient has been cured, and longer follow-up is needed to determine how durable the responses are.

The results come from a small, early-stage study rather than a randomized comparison with chemotherapy alone. Larger trials will be needed to confirm the drug combination’s effectiveness and safety.

HOW THIS STORY WAS MADE

Written from 8 articles, 3 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one (7 if wire copies count as one too); this version written 48 h after the record first saw the story; the editor kept it as written.

Publishers
20
Source articles
24
Given to the writer
8, 3 with the article's own text
Independent newsrooms
8 (7 if wire copies count as one)
This version written
48 h after the record first saw the story
Second model (editor)
kept as written
Publication gate
passed
Human review
none

WHAT THE EDITOR DID

The second model checked the writer's draft against the same sources and published it as written.

Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →

OUTLETS CARRYING THE STORY, RUN BY RUN

0 10 20 20 Nov 21 Nov 22 Nov 21 Nov 00:25 UTC · Daraxonrasib-chemotherapy combination shows promise in early pancreatic cancer trial 21 Nov 18:24 UTC · Daraxonrasib combination shows early promise in metastatic pancreatic cancer trial

WHAT HELD, WHAT CAME LATER

From the first reports to the latest

  • Nothing ran from the first third of the coverage to the last.

Entered the story later

  • 76.6% patients alive · from 20 Nov 09:36, 2 outlets
  • 18 months your · from 20 Nov 09:36, 2 outlets
  • Wungki Park · from 20 Nov 09:36, 2 outlets
  • Michelle Mitchell · from 20 Nov 09:36, 2 outlets

Figures reported with different numbers

  • cent patients: 60.7 (1 from 21 Nov 08:33) → 90 (1 from 21 Nov 08:33) → 90.2 (1 from 21 Nov 08:33) → 8 (1 from 21 Nov 12:25)

Matched by pattern, not read: a different number can be a correction, a rising count, or two different counts.

HOW THIS STORY DEVELOPED: EVERY HEADLINE, EVERY OUTLET →